Vascular calcification: From pathophysiology to biomarkers

Clinica Chimica Acta

Volumn 438, Issue , 2014, Pages 401-414

  Evrard, Séverine ^a   Delanaye, P ^a   Kamel, Said ^b,c   Cristol, Jean Paul ^d   Cavalier, Etienne ^a   Arnaud, J ^e   Zaoui, Ph ^e   Carlier, M C ^f   Laville, M ^f   Fouque, D ^f   Cristol, J P ^g   Bargnoux, A S ^g   Kamel, S ^b,h   Massy, Z ^b,i   Prie D ^h   Urena Torres, P ^h   Souberbielle, J C ^h   Boutten, A ^j,k   Hannedouche, T ^m   Jean, G ⁿ   Lafage Proust, M H ^o   London, G ^p   Mercadal, L ^q   Pieroni, L ^r   more..

^a UNIVERSITY OF LIÈGE   (Belgium)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f HOSPICES CIVILS DE LYON   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h INSERM   (France)

ⁱ University Ambroise Paré Hospital   (France)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k Centre de recherche sur l'habitat ENSA Paris Val de Seine   (France)

^l CH de Manhes   (France)

^m UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁿ Nephrocare Tassin Charcot   (France)

^o UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^p PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^q Salptrière Hospital   (France)

^r CH Avignon   (France)

more..

Author keywords

Bone morphogenetic protein 2; Fetuin A; Fibroblast growth factor 23; Matrix Gla protein; Osteoprotegerin; Vascular calcification

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; FETUIN A; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MATRIX GLA PROTEIN; MEMBRANE PROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEONECTIN; OSTEOPONTIN; OSTEOPROTEGERIN; PYROPHOSPHATE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCLEROSTIN; UNCLASSIFIED DRUG; BMP2 PROTEIN, HUMAN; CALCIUM BINDING PROTEIN; FIBROBLAST GROWTH FACTOR; SCLEROPROTEIN; TNFRSF11B PROTEIN, HUMAN;

BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; BONE TURNOVER; DISEASE ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; MINERALIZATION; NONHUMAN; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETES MELLITUS; DYSLIPIDEMIA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION;

ALPHA-2-HS-GLYCOPROTEIN; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEIN 2; CALCIUM-BINDING PROTEINS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DYSLIPIDEMIAS; EXTRACELLULAR MATRIX PROTEINS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HUMANS; OSTEOPROTEGERIN; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION;

EID: 84908402891     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.08.034     Document Type: Review

References (204)

1. Murphy W.A., Nedden Dz D., Gostner P., Knapp R., Recheis W., Seidler H. The iceman: discovery and imaging. Radiology 2003, 226:614-629.
2. Virchow R. Arch Pathol Anat 1855, 8:103-113.
3. Hofmann Bowman M.A., McNally E.M. Genetic pathways of vascular calcification. Trends Cardiovasc Med 2012, 22:93-98.
4. Kapustin A.N., Davies J.D., Reynolds J.L., et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 2011, 109:e1-e12.
5. Giachelli C.M. Vascular calcification mechanisms. J Am Soc Nephrol 2004, 15:2959-2964.
6. Rutsch F., Nitschke Y., Terkeltaub R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res 2011, 109:578-592.
7. Assimes T.L., Knowles J.W., Basu A., et al. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet 2008, 17:2320-2328.
8. Lange L.A., Lange E.M., Bielak L.F., et al. Autosomal genome-wide scan for coronary artery calcification loci in sibships at high risk for hypertension. Arterioscler Thromb Vasc Biol 2002, 22:418-423.
9. O'Donnell C.J., Kavousi M., Smith A.V., et al. Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation 2011, 124:2855-2864.
10. Myocardial Infarction Genetics Consortium, Kathiresan S., Voight B.F., et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009, 41:334-341.
11. Li Q., Jiang Q., Schurgers L.J., Uitto J. Pseudoxanthoma elasticum: reduced gamma-glutamyl carboxylation of matrix gla protein in a mouse model (Abcc6-/-). Biochem Biophys Res Commun 2007, 364:208-213.
12. Moe S.M., Duan D., Doehle B.P., O'Neill K.D., Chen N.X. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003, 63:1003-1011.
13. Giachelli C.M. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003, 14:S300-S304.
14. Jono S., McKee M.D., Murry C.E., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000, 87:E10-E17.
15. Li X., Yang H.Y., Giachelli C.M. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006, 98:905-912.
16. Steitz S.A., Speer M.Y., Curinga G., et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001, 89:1147-1154.
17. Mizobuchi M., Towler D., Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009, 20:1453-1464.
18. Giachelli C.M., Bae N., Almeida M., Denhardt D.T., Alpers C.E., Schwartz S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993, 92:1686-1696.
19. Levy R.J., Schoen F.J., Levy J.T., Nelson A.C., Howard S.L., Oshry L.J. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol 1983, 113:143-155.
20. Reynolds J.L., Joannides A.J., Skepper J.N., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004, 15:2857-2867.
21. Kapustin A.N., Shanahan C.M. Calcium regulation of vascular smooth muscle cell-derived matrix vesicles. Trends Cardiovasc Med 2012, 22:133-137.
22. Kendrick J., Chonchol M. The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis 2011, 58:826-834.
23. Giachelli C.M., Speer M.Y., Li X., Rajachar R.M., Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 2005, 96:717-722.
24. Kim K.M. Apoptosis and calcification. Scanning Microsc 1995, 9:1137-1175. [discussion 1175-1138].
25. Kockx M.M., De Meyer G.R., Muhring J., Jacob W., Bult H., Herman A.G. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998, 97:2307-2315.
26. Proudfoot D., Skepper J.N., Hegyi L., Bennett M.R., Shanahan C.M., Weissberg P.L. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000, 87:1055-1062.
27. Pal S.N., Golledge J. Osteo-progenitors in vascular calcification: a circulating cell theory. J Atheroscler Thromb 2011, 18:551-559.
28. Tang Z., Wang A., Yuan F., et al. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat Commun 2012, 3:875.
29. Shanahan C.M., Crouthamel M.H., Kapustin A., Giachelli C.M. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011, 109:697-711.
30. Sutra T., Morena M., Bargnoux A.S., Caporiccio B., Canaud B., Cristol J.P. Superoxide production: a procalcifying cell signalling event in osteoblastic differentiation of vascular smooth muscle cells exposed to calcification media. Free Radic Res 2008, 42:789-797.
31. Byon C.H., Javed A., Dai Q., et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008, 283:15319-15327.
32. Shao J.S., Cheng S.L., Pingsterhaus J.M., Charlton-Kachigian N., Loewy A.P., Towler D.A. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005, 115:1210-1220.
33. Lee H.L., Woo K.M., Ryoo H.M., Baek J.H. Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun 2010, 391:1087-1092.
34. Tintut Y., Patel J., Parhami F., Demer L.L. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000, 102:2636-2642.
35. Tintut Y., Patel J., Territo M., Saini T., Parhami F., Demer L.L. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 2002, 105:650-655.
36. Aikawa E., Nahrendorf M., Figueiredo J.L., et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007, 116:2841-2850.
37. Shanahan C.M. Inflammation ushers in calcification: a cycle of damage and protection?. Circulation 2007, 116:2782-2785.
38. Smith E.R., Ford M.L., Tomlinson L.A., Rajkumar C., McMahon L.P., Holt S.G. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 2012, 27:1957-1966.
39. Menini S., Iacobini C., Ricci C., et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res 2013, 100:472-480.
40. Averill M.M., Kerkhoff C., Bornfeldt K.E. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 2012, 32:223-229.
41. Hofmann Bowman M.A., Schmidt A.M. S100/calgranulins EN-RAGEing the blood vessels: implications for inflammatory responses and atherosclerosis. Am J Cardiovasc Dis 2011, 1:92-100.
42. Caudrillier A., Mentaverri R., Brazier M., Kamel S., Massy Z.A. Calcium-sensing receptor as a potential modulator of vascular calcification in chronic kidney disease. J Nephrol 2010, 23:17-22.
43. Alam M.U., Kirton J.P., Wilkinson F.L., et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009, 81:260-268.
44. Ivanovski O., Nikolov I.G., Joki N., et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis 2009, 205:55-62.
45. Henaut L., Boudot C., Massy Z.A., et al. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action. Cardiovasc Res 2014, 101:256-265.
46. Parhami F., Tintut Y., Ballard A., Fogelman A.M., Demer L.L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001, 88:954-960.
47. Zeadin M., Butcher M., Werstuck G., Khan M., Yee C.K., Shaughnessy S.G. Effect of leptin on vascular calcification in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2009, 29:2069-2075.
48. Hill J.A., Olson E.N., Griendling K.K., Kitsis R.N., Stull J.T. Muscle: fundamental biology and mechanisms of disease 2012, Elsevier Science & Technology Books.
49. Doherty T.M., Uzui H., Fitzpatrick L.A., et al. Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J 2002, 16:577-582.
50. Mozar A., Haren N., Chasseraud M., et al. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol 2008, 215:47-54.
51. Moe S.M., O'Neill K.D., Duan D., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002, 61:638-647.
52. Ketteler M., Biggar P.H. Review article: Getting the balance right: assessing causes and extent of vascular calcification in chronic kidney disease. Nephrology 2009, 14:389-394.
53. Goldsmith D., Ritz E., Covic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease?. Kidney Int 2004, 66:1315-1333.
54. Braun J., Oldendorf M., Moshage W., Heidler R., Zeitler E., Luft F.C. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996, 27:394-401.
55. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004, 15:1943-1951.
56. London G.M., Marchais S.J., Guerin A.P., Boutouyrie P., Metivier F., de Vernejoul M.C. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008, 19:1827-1835.
57. Barreto D.V., Barreto F.C., Carvalho A.B., et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005, 67:1576-1582.
58. Adragao T., Herberth J., Monier-Faugere M.C., et al. Low bone volume-a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 2009, 4:450-455.
59. Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000, 35:1226-1237.
60. Ganesh S.K., Stack A.G., Levin N.W., Hulbert-Shearon T., Port F.K. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001, 12:2131-2138.
61. Naves-Diaz M., Passlick-Deetjen J., Guinsburg A., et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011, 26:1938-1947.
62. Floege J., Kim J., Ireland E., et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011, 26:1948-1955.
63. Coen G., Manni M., Mantella D., et al. Are PTH serum levels predictive of coronary calcifications in haemodialysis patients?. Nephrol Dial Transplant 2007, 22:3262-3267.
64. Coen G. Calcimimetics, parathyroid hormone, and vascular calcification in chronic kidney disease. Kidney Int 2008, 74:1229-1231.
65. Shao J.S., Cheng S.L., Charlton-Kachigian N., Loewy A.P., Towler D.A. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003, 278:50195-50202.
66. Neves K.R., Graciolli F.G., dos Reis L.M., et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007, 71:1262-1270.
67. Prie D., Torres P.U., Friedlander G. A new axis of phosphate balance control: fibroblast growth factor 23-Klotho. Nephrol Ther 2009, 5:513-519.
68. Hu P., Xuan Q., Hu B., Lu L., Wang J., Qin Y.H. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease. Int J Biol Sci 2012, 8:663-671.
69. Toussaint N.D., Pedagogos E., Tan S.J., et al. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology 2012, 17:433-444.
70. Stubbs J.R., Liu S., Tang W., et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007, 18:2116-2124.
71. Balci M., Kirkpantur A., Gulbay M., Gurbuz O.A. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int 2010, 14:425-432.
72. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
73. Scialla J.J., Lau W.L., Reilly M.P., et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013, 83:1159-1168.
74. Jean G., Terrat J.C., Vanel T., et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009, 24:2792-2796.
75. Jean G., Bresson E., Terrat J.C., et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009, 24:948-955.
76. Coen G., De Paolis P., Ballanti P., et al. Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J Nephrol 2011, 24:313-321.
77. Desjardins L., Liabeuf S., Renard C., et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012, 23:2017-2025.
78. Inaba M., Okuno S., Imanishi Y., et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006, 17:1506-1513.
79. Nasrallah M.M., El-Shehaby A.R., Salem M.M., Osman N.A., El Sheikh E., Sharaf El Din U.A. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010, 25:2679-2685.
80. Schoppet M., Hofbauer L.C., Brinskelle-Schmal N., et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab 2012, 97:E575-E583.
81. Masai H., Joki N., Sugi K., Moroi M. A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease. Atherosclerosis 2013, 226:228-233.
82. Xiao D.M., Wu Q., Fan W.F., Ye X.W., Niu J.Y., Gu Y. Effect of serum FGF-23, MGP and fetuin-A on calcium-phosphate metabolism in maintenance hemodialysis patients. Hemodial Int 2013, 17(4):483-492.
83. Lee C.T., Chua S., Hsu C.Y., et al. Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Dis Markers 2013, 34:229-235.
84. Parker B.D., Schurgers L.J., Brandenburg V.M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
85. Morena M., Jaussent I., Halkovich A., et al. Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. PLoS One 2012, 7:e36175.
86. Massy Z.A., Drueke T.B. Vascular calcification. Curr Opin Nephrol Hypertens 2013, 22:405-412.
87. Prie D., Urena Torres P., Friedlander G. Fibroblast growth factor 23-klotho: a new axis of phosphate balance control. Med Sci 2009, 25:489-495.
88. Bacchetta J., Cochat P., Salusky I.B. FGF23 and klotho: the new cornerstones of phosphate/calcium metabolism. Arch Pediatr 2011, 18:686-695.
89. Lau W.L., Leaf E.M., Hu M.C., et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012, 82:1261-1270.
90. Hu M.C., Kuro-o M., Moe O.W. Renal and extrarenal actions of Klotho. Semin Nephrol 2013, 33:118-129.
91. Ketteler M., Bongartz P., Westenfeld R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003, 361:827-833.
92. Oikawa O., Higuchi T., Yamazaki T., Yamamoto C., Fukuda N., Matsumoto K. Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. Clin Exp Nephrol 2007, 11:304-308.
93. Wang A.Y., Woo J., Wang M., et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001, 12:1927-1936.
94. Schafer C., Heiss A., Schwarz A., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112:357-366.
95. Westenfeld R., Schafer C., Kruger T., et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol 2009, 20:1264-1274.
96. Heiss A., DuChesne A., Denecke B., et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003, 278:13333-13341.
97. Price P.A., Lim J.E. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003, 278:22144-22152.
98. Smith E.R., Hanssen E., McMahon L.P., Holt S.G. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One 2013, 8:e60904.
99. Reynolds J.L., Skepper J.N., McNair R., et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005, 16:2920-2930.
100. Chen N.X., O'Neill K.D., Chen X., et al. Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins. Am J Physiol Renal Physiol 2007, 292:F599-F606.
101. Sage A.P., Tintut Y., Demer L.L. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010, 7:528-536.
102. Moe S.M., Reslerova M., Ketteler M., et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005, 67:2295-2304.
103. Abdel-Wahab A.F., Fathy O., Al-Harizy R. Negative correlation between fetuin-A and indices of vascular disease in systemic lupus erythematosus patients with and without lupus nephritis. Arab J Nephrol Transplant 2013, 6:11-20.
104. Jung J.Y., Hwang Y.H., Lee S.W., et al. Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrol Dial Transplant 2010, 25:4041-4048.
105. Chen H.Y., Chiu Y.L., Hsu S.P., Pai M.F., Yang J.Y., Peng Y.S. Low serum fetuin A levels and incident stroke in patients with maintenance haemodialysis. Eur J Clin Invest 2013, 43:387-396.
106. Marechal C., Schlieper G., Nguyen P., et al. Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. Clin J Am Soc Nephrol 2011, 6:974-985.
107. Jung H.H., Baek H.J., Kim S.W. Fetuin-A, coronary artery calcification and outcome in maintenance hemodialysis patients. Clin Nephrol 2011, 75:391-396.
108. Manghat P., Souleimanova I., Cheung J., et al. Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone 2011, 48:1127-1132.
109. Hermans M.M., Brandenburg V., Ketteler M., et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006, 21:1293-1299.
110. Hamano T., Matsui I., Mikami S., et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 2010, 21:1998-2007.
111. Tousoulis D., Siasos G., Maniatis K., et al. Novel biomarkers assessing the calcium deposition in coronary artery disease. Curr Med Chem 2012, 19:901-920.
112. Luo G., Ducy P., McKee M.D., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997, 386:78-81.
113. Khavandgar Z., Roman H., Li J., et al. Elastin haploinsufficiency impedes the progression of arterial calcification in MGP-deficient mice. J Bone Miner Res 2013.
114. Roy M.E., Nishimoto S.K. Matrix Gla protein binding to hydroxyapatite is dependent on the ionic environment: calcium enhances binding affinity but phosphate and magnesium decrease affinity. Bone 2002, 31:296-302.
115. Sweatt A., Sane D.C., Hutson S.M., Wallin R. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003, 1:178-185.
116. Lomashvili K.A., Wang X., Wallin R., O'Neill W.C. Matrix Gla protein metabolism in vascular smooth muscle and role in uremic vascular calcification. J Biol Chem 2011, 286:28715-28722.
117. Schurgers L.J., Uitto J., Reutelingsperger C.P. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med 2013, 19:217-226.
118. Price P.A., Toroian D., Lim J.E. Mineralization by inhibitor exclusion: the calcification of collagen with fetuin. J Biol Chem 2009, 284:17092-17101.
119. Schurgers L.J., Teunissen K.J., Knapen M.H., et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005, 25:1629-1633.
120. Murshed M., Schinke T., McKee M.D., Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004, 165:625-630.
121. Cranenburg E.C., Brandenburg V.M., Vermeer C., et al. Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 2009, 101:359-366.
122. Schurgers L.J., Barreto D.V., Barreto F.C., et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010, 5:568-575.
123. Schlieper G., Westenfeld R., Kruger T., et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011, 22:387-395.
124. Price P.A., Faus S.A., Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998, 18:1400-1407.
125. Koos R., Mahnken A.H., Muhlenbruch G., et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005, 96:747-749.
126. Schurgers L.J., Spronk H.M., Soute B.A., Schiffers P.M., DeMey J.G., Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007, 109:2823-2831.
127. Li X., Yang H.Y., Giachelli C.M. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008, 199:271-277.
128. Abe E., Yamamoto M., Taguchi Y., et al. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res 2000, 15:663-673.
129. Yao Y., Bennett B.J., Wang X., et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res 2010, 107:485-494.
130. Roedel E.K., Schwarz E., Kanse S.M. The factor VII-activating protease (FSAP) enhances the activity of bone morphogenetic protein-2 (BMP-2). J Biol Chem 2013, 288:7193-7203.
131. Balderman J.A., Lee H.Y., Mahoney C.E., et al. Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification. J Am Heart Assoc 2012, 1:e003905.
132. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
133. Bennett B.J., Scatena M., Kirk E.A., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006, 26:2117-2124.
134. Collin-Osdoby P., Rothe L., Bekker S., Anderson F., Huang Y., Osdoby P. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J Bone Miner Res 2002, 17:1859-1871.
135. Bucay N., Sarosi I., Dunstan C.R., et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
136. Morony S., Sage A.P., Corbin T., Lu J., Tintut Y., Demer L.L. Enhanced mineralization potential of vascular cells from SM22alpha-Rankl (tg) mice. Calcif Tissue Int 2012, 91:379-386.
137. Zhou S., Fang X., Xin H., Li W., Qiu H., Guan S. Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jkappa/Msx2 signaling pathway. PLoS One 2013, 8:e68987.
138. Morena M., Dupuy A.M., Jaussent I., et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 2009, 24:3389-3397.
139. Morena M., Terrier N., Jaussent I., et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006, 17:262-270.
140. Hwang J.J., Wei J., Abbara S., Grinspoon S.K., Lo J. Receptor activator of nuclear factor-kappaB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. J Acquir Immune Defic Syndr 2012, 61:359-363.
141. Ozkok A., Caliskan Y., Sakaci T., et al. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol 2012, 7:965-973.
142. Albu A., Fodor D., Bondor C., Craciun A.M. Bone metabolism regulators and arterial stiffness in postmenopausal women. Maturitas 2013, 76:146-150.
143. Meneghini M., Regalia A., Alfieri C., et al. Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney transplantation. Transplantation 2013, 96:42-48.
144. Svensson M., Dahle D.O., Mjoen G., et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrol Dial Transplant 2012, 27:2571-2575.
145. Gordin D., Soro-Paavonen A., Thomas M.C., et al. Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes Care 2013, 36:1827-1833.
146. Winther S., Christensen J.H., Flyvbjerg A., et al. Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clin Nephrol 2013, 80:161-167.
147. Scialla J.J., Leonard M.B., Townsend R.R., et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:2612-2619.
148. Aoki A., Murata M., Asano T., et al. Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. Cardiovasc Diabetol 2013, 12:11.
149. Tousoulis D., Siasos G., Maniatis K., et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2013, 167:1924-1928.
150. Olesen M., Skov V., Mechta M., Mumm B.H., Rasmussen L.M. No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. Mol Cell Endocrinol 2012, 362:149-156.
151. Deuell K.A., Callegari A., Giachelli C.M., Rosenfeld M.E., Scatena M. RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-alpha. J Vasc Res 2012, 49:510-521.
152. Morony S., Tintut Y., Zhang Z., et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008, 117:411-420.
153. Helas S., Goettsch C., Schoppet M., et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009, 175:473-478.
154. Samelson E.J., Miller P.D., Christiansen C., et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res 2014, 29:450-457.
155. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2302-2309.
156. Speer M.Y., McKee M.D., Guldberg R.E., et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002, 196:1047-1055.
157. Jono S., Peinado C., Giachelli C.M. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000, 275:20197-20203.
158. Wada T., McKee M.D., Steitz S., Giachelli C.M. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999, 84:166-178.
159. Qin X., Corriere M.A., Matrisian L.M., Guzman R.J. Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol 2006, 26:1510-1516.
160. Berezin A.E., Kremzer A.A. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 2013, 229:475-481.
161. Kadoglou N.P., Papadakis I., Moulakakis K.G., et al. Arterial stiffness and novel biomarkers in patients with abdominal aortic aneurysms. Regul Pept 2012, 179:50-54.
162. Kiefer F.W., Zeyda M., Gollinger K., et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010, 59:935-946.
163. Zheng Y., Wang Z., Deng L., et al. Osteopontin promotes inflammation in patients with acute coronary syndrome through its activity on IL-17 producing cells. Eur J Immunol 2012, 42:2803-2814.
164. Bazzichi L., Ghiadoni L., Rossi A., et al. Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis. Mol Med 2009, 15:402-406.
165. Sun J., Xu Y., Dai Z., Sun Y. Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin. Mol Cell Endocrinol 2009, 313:64-69.
166. Gadeau A.P., Chaulet H., Daret D., Kockx M., Daniel-Lamaziere J.M., Desgranges C. Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury. J Histochem Cytochem 2001, 49:79-86.
167. Bini A., Mann K.G., Kudryk B.J., Schoen F.J. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 1999, 19:1852-1861.
168. van de Loo P.G.F., Soute B.A.M., van Haarlem L.J.M., Vermeer C. The effect of Gla-containing proteins on the precipitation of insoluble salts. Biochem Biophys Res Commun 1987, 142:113-119.
169. Levy R.J., Gundberg C., Scheinman R. The identification of the vitamin K-dependent bone protein osteocalcin as one of the gamma-carboxyglutamic acid containing proteins present in calcified atherosclerotic plaque and mineralized heart valves. Atherosclerosis 1983, 46:49-56.
170. Hunter G.K., Hauschka P.V., Poole A.R., Rosenberg L.C., Goldberg H.A. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 1996, 317(Pt 1):59-64.
171. Ducy P., Desbois C., Boyce B., et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996, 382:448-452.
172. Kavukcuoglu N.B., Patterson-Buckendahl P., Mann A.B. Effect of osteocalcin deficiency on the nanomechanics and chemistry of mouse bones. J Mech Behav Biomed Mater 2009, 2:348-354.
173. Roy M.E., Nishimoto S.K., Rho J.Y., Bhattacharya S.K., Lin J.S., Pharr G.M. Correlations between osteocalcin content, degree of mineralization, and mechanical properties of C. carpio rib bone. J Biomed Mater Res 2001, 54:547-553.
174. Idelevich A., Rais Y., Monsonego-Ornan E. Bone Gla protein increases HIF-1alpha-dependent glucose metabolism and induces cartilage and vascular calcification. Arterioscler Thromb Vasc Biol 2011, 31:e55-e71.
175. Flammer A.J., Gossl M., Widmer R.J., et al. Osteocalcin positive CD133+/CD34-/KDR+progenitor cells as an independent marker for unstable atherosclerosis. Eur Heart J 2012, 33:2963-2969.
176. Fadini G.P., Albiero M., Menegazzo L., et al. Procalcific phenotypic drift of circulating progenitor cells in type 2 diabetes with coronary artery disease. Exp Diabetes Res 2012, 2012:921685.
177. Osorio A., Ortega E., Torres J.M., Sanchez P., Ruiz-Requena E. Biochemical markers of vascular calcification in elderly hemodialysis patients. Mol Cell Biochem 2013, 374:21-27.
178. Osorio A., Ortega E., Torres J.M., Sanchez P., Ruiz-Requena E. Mineral-bone metabolism markers in young hemodialysis patients. Clin Biochem 2011, 44:1425-1428.
179. Kim K.J., Kim K.M., Park K.H., et al. Aortic calcification and bone metabolism: the relationship between aortic calcification, BMD, vertebral fracture, 25-hydroxyvitamin D, and osteocalcin. Calcif Tissue Int 2012, 91:370-378.
180. Harmey D., Hessle L., Narisawa S., Johnson K.A., Terkeltaub R., Millan J.L. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004, 164:1199-1209.
181. Rutsch F., Ruf N., Vaingankar S., et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003, 34:379-381.
182. Johnson K., Polewski M., van Etten D., Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol 2005, 25:686-691.
183. Towler D.A. Inorganic pyrophosphate: a paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol 2005, 25:651-654.
184. Ketteler M., Floege J. Calcification and the usual suspect phosphate: still guilty but there are other guys behind the scenes. Nephrol Dial Transplant 2006, 21:33-35.
185. Murshed M., Harmey D., Millan J.L., McKee M.D., Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005, 19:1093-1104.
186. Villa-Bellosta R., Sorribas V. Prevention of vascular calcification by polyphosphates and nucleotides- role of ATP. Circ J 2013, 77:2145-2151.
187. Lomashvili K.A., Khawandi W., O'Neill W.C. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005, 16:2495-2500.
188. O'Neill W.C., Sigrist M.K., McIntyre C.W. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010, 25:187-191.
189. Riser B.L., Barreto F.C., Rezg R., et al. Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrol Dial Transplant 2011, 26:3349-3357.
190. O'Neill W.C., Lomashvili K.A., Malluche H.H., Faugere M.C., Riser B.L. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011, 79:512-517.
191. Villa-Bellosta R., Sorribas V. Calcium phosphate deposition with normal phosphate concentration. -Role of pyrophosphate. Circ J 2011, 75:2705-2710.
192. Lomashvili K.A., Monier-Faugere M.C., Wang X., Malluche H.H., O'Neill W.C. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009, 75:617-625.
193. Zhou S., Fang X., Xin H., Guan S. Effects of alendronate on the Notch1RBPJkappa signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells. Mol Med Rep 2013, 8:89-94.
194. Balemans W., Ebeling M., Patel N., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
195. Brunkow M.E., Gardner J.C., Van Ness J., et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
196. Joiner D.M., Ke J., Zhong Z., Xu H.E., Williams B.O. LRP5 and LRP6 in development and disease. Trends Endocrinol Metab 2013, 24:31-39.
197. Krishnan V., Bryant H.U., Macdougald O.A. Regulation of bone mass by Wnt signaling. J Clin Invest 2006, 116:1202-1209.
198. Robling A.G., Niziolek P.J., Baldridge L.A., et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283:5866-5875.
199. Koos R., Brandenburg V., Mahnken A.H., et al. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis 2013, 22:317-325.
200. Hampson G., Edwards S., Conroy S., Blake G.M., Fogelman I., Frost M.L. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 2013, 56:42-47.
201. Szulc P., Bertholon C., Borel O., Marchand F., Chapurlat R. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res 2013, 28:855-864.
202. Morales-Santana S., Garcia-Fontana B., Garcia-Martin A., et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 2013, 36:1667-1674.
203. Claes K.J., Viaene L., Heye S., Meijers B., d'Haese P., Evenepoel P. Sclerostin: Another vascular calcification inhibitor?. J Clin Endocrinol Metab 2013, 98:3221-3228.
204. Sabbagh Y., Graciolli F.G., O'Brien S., et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012, 27:1757-1772.